Question 1

What are the potential side effects of the combination treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the The Combination of Fruquintinib, Tislelizumab and Stereotactic Ablative Radiotherapy in Metastatic Colorectal Cancer(RIFLE) clinical trial (NCT04948034). Contact the study team or your healthcare provider for specific answers.

Question 2

How does this treatment compare to my current options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the The Combination of Fruquintinib, Tislelizumab and Stereotactic Ablative Radiotherapy in Metastatic Colorectal Cancer(RIFLE) clinical trial (NCT04948034). Contact the study team or your healthcare provider for specific answers.

Question 3

What will the treatment schedule look like for me?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the The Combination of Fruquintinib, Tislelizumab and Stereotactic Ablative Radiotherapy in Metastatic Colorectal Cancer(RIFLE) clinical trial (NCT04948034). Contact the study team or your healthcare provider for specific answers.

Question 4

How will my progress be monitored during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the The Combination of Fruquintinib, Tislelizumab and Stereotactic Ablative Radiotherapy in Metastatic Colorectal Cancer(RIFLE) clinical trial (NCT04948034). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if I experience side effects?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the The Combination of Fruquintinib, Tislelizumab and Stereotactic Ablative Radiotherapy in Metastatic Colorectal Cancer(RIFLE) clinical trial (NCT04948034). Contact the study team or your healthcare provider for specific answers.

Question 6

Are there any costs or logistical considerations I should be aware of?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the The Combination of Fruquintinib, Tislelizumab and Stereotactic Ablative Radiotherapy in Metastatic Colorectal Cancer(RIFLE) clinical trial (NCT04948034). Contact the study team or your healthcare provider for specific answers.

What this study is about